Epigenetic Therapy

DNA methylation Three main mechanisms - modifications of histones and changes in noncoding RNA - have been elucidated in epigenetics. In different ways, can provide the industry with a greater understanding into the mechanism underlying disease, act as a potential source of biomarkers of disease and provide new targets for therapeutic intervention.

In addition to the DNA of every day tools of analysis, epigenetic researchers have had to adopt more complex technologies such as chromatin immunoprecipitation (ChIP) and DNA methylation methodologies and to develop analytical tools to decipher the large amount of epigenetic information. The progress of these technologies should allow epigenetic research to reduce costs and increase the samples make it more commercially attractive in the industry to discover and validate new biomarkers epigenetic targets for the development of diagnostics and drugs.

epigenetic medicine has arrived. The market is over $ 560 million from the sale of three anticancer drugs that target the two epigenetic pathways - DNA methyltransferase (DNMT) and histone deacteylase (HDAC) - and thirty epigenetic drugs are being developed more a dozen biotechnology companies. These drugs are mainly focused on the treatment of cancer, neurodegenerative diseases and infectious diseases, although research is underway to explore the role of epigenetics in cardiovascular, metabolic, and other eye diseases. While this market is still in its infancy KOL think he is on the verge of a revolution, one that could change the way patients are diagnosed and treated in the future.

The main features of this report

aec Identify the leading companies at the forefront of research in epigenetics, which drive the market to develop a new generation of epigenetic therapies and diagnostics.

aec Provide case studies of leading companies developing epigenetic therapies to treat cancer, neurodegenerative diseases and infectious diseases.

aec Analyze key trends and issues facing the development of epigenetic therapies.

aec Review alliances, mergers, acquisitions and business strategies adopted by the biotech and large pharmaceutical companies to capitalize on the latest developments in epigenetics.

Scope of this report

aec Identify the leading companies in the field of epigenetic research a wide range of therapeutic areas

aec The company's strategies for their review and development of their programs epigenetic

aec Learn more about the latest developments in epigenetic research and how non-coding RNAs may open Pandora's box for other epigenetic research.

aec Identify innovative pharmaceutical companies and discover the strategies they adopt to exploit the potential both as epigenetic biomarkers of disease and targets for therapeutic intervention

Market issues

aec The productivity of the industry in decline: It is well documented that productivity in the pharmaceutical industry has declined over the past 15 years. The identification of new biomarkers of disease could aid the process R & D and support the preclinical and clinical development of small molecule therapeutics.

aec Innovative new classes of drugs: The identification of mechanisms underlying disease could identify new targets
for small molecule therapeutic intervention that can be used alone or in combination with traditional therapies
extend their use.

The main conclusions of this report

aec New therapies epigenetic entered the market. The first drugs were approved in 2006 for the treatment of cancer and a host of new small molecule therapies are currently being developed that are more selective and target different classes of chromatin modifying enzymes to enable a more targeted approach to treatment .